A Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study for Relapsed/Refractory (R/R) Autoimmune Diseases
Latest Information Update: 22 May 2025
At a glance
- Drugs UTAA 91 (Primary)
- Indications Autoimmune disorders; Interstitial lung diseases; Myositis; Primary biliary cirrhosis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Systemic scleroderma; Thrombocytopenia
- Focus Adverse reactions
- Sponsors PersonGen Biotherapeutics
Most Recent Events
- 22 May 2025 New trial record